Laura J Esserman, Donald A Berry, Maggie C U Cheang, Christina Yau, Charles M Perou, Lisa Carey, Angela DeMichele, Joe W Gray, Kathleen Conway-Dorsey, Marc E Lenburg, Meredith B Buxton, Sarah E Davis, Laura J van't Veer, Clifford Hudis, Koei Chin, Denise Wolf, Helen Krontiras, Leslie Montgomery, Debu Tripathy, Constance Lehman, Minetta C Liu, Olufunmilayo I Olopade, Hope S Rugo, John T Carpenter, Chad Livasy, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunni-Yi Chen, Dilip Giri, Alfred Au, Nola Hylton
Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥ 3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated...
April 2012: Breast Cancer Research and Treatment